Medacta Grows Near 10% in Constant Currency, Shares Drop 6.2%

Medacta Group SA (MEDGF) reported nearly 10% constant-currency revenue growth for the first half of its 2026 financial year while flagging foreign-exchange headwinds, softness in the US market and strike disruption in Spain, and its shares last traded at 150.06, down 6.21% on 11 September 2026.

Medacta Group SA (MEDGF) told investors on its first-half fiscal 2026 earnings call that revenue grew by nearly 10% in constant currency, a double-digit-adjacent result that the orthopaedic implant maker delivered against three separate drags: an unfavourable foreign-exchange backdrop, a softer United States market, and strike action in Spain that disrupted elective surgical activity. The market's response was unsentimental. MEDGF last traded at 150.06 on Friday, 11 September 2026, down 6.21% from the previous close of 160.00 — a fall of 9.94 points on the quote — while the broad US indices closed higher.

Constant currency is doing a lot of work in that number

"Constant currency" strips out the effect of exchange-rate movements by translating this period's foreign sales at last period's rates. For a Swiss-domiciled medical device company selling into the United States, Europe, Asia-Pacific and beyond, the distinction is not cosmetic. Costs sit heavily in a strong home currency; revenue arrives in dollars, euros, yen and Australian dollars. When those currencies weaken against the reporting currency, reported growth lands materially below the underlying commercial performance, even though nothing about surgeon demand or implant volumes has changed.

That is the gap management asked investors to look through on the call, which was covered in detail by GuruFocus. The company paired the near-10% constant-currency figure with an explicit acknowledgement of FX headwinds and margin pressure — the standard shape of a period in which the operating business is expanding faster than the income statement shows.

Investors have seen this pattern across European medtech and industrials through 2026. The question that decides whether a currency drag is a footnote or a problem is duration. A single half of translation loss is arithmetic. Several consecutive halves start to compress the absolute cash generated from the same unit volume, which is where reinvestment in instrument sets, surgical robotics and salesforce expansion begins to feel the squeeze.

Two operational problems, only one of them structural

The two country-level issues Medacta flagged are not equivalent, and lumping them together would misread the half.

• Spanish strikes are an exogenous, time-boxed disruption. When hospital staff strike, elective orthopaedic procedures — hip and knee replacements above all — get postponed rather than cancelled. The backlog does not evaporate; it slides into a later period. Revenue timing suffers, underlying demand does not. Investors should treat this as a deferral and watch whether the catch-up shows up in the second half.
• US market softness is the one that matters. The United States is the largest and most profitable orthopaedic implant market in the world, and it is where pricing, hospital purchasing behaviour and competitive share shifts show up first. Softness there can mean any of several things: hospital capital and procedure scheduling running cooler, a sales-territory transition, or share loss to larger incumbents. Management framed a rebound as something it is confident in — which makes the second half the test of that claim.

The distinction matters for how much weight to put on the headline growth rate. Near-10% constant-currency expansion that includes a soft US contribution implies the rest of the portfolio — Europe outside Spain, Asia-Pacific, and the distributor markets — grew faster than the group average. That is a reasonable base case, though the company's regional breakdown is what would confirm it.

Margin pressure alongside growth is the harder combination

Growth with margin compression is a more awkward message than either one alone. Revenue that expands while the margin narrows tends to come from some mix of: currency translation hitting revenue harder than it hits a domestically weighted cost base; price concessions to win or hold hospital contracts; front-loaded investment in instrumentation and implant inventory ahead of the revenue it will generate; and geographic mix shifting toward lower-margin markets.

For a company in Medacta's position — mid-cap, differentiated by minimally invasive surgical technique and personalised implant planning rather than by scale — the third of those is often the intentional one. Placing instrument kits with new surgeons is a working-capital and depreciation cost that lands before the implant volume does. The distinction between margin pressure that reflects investment and margin pressure that reflects price erosion is the single most useful thing to extract from the full disclosure.

What the share reaction is saying

The 6.21% decline on the day, against a close of 150.06, is a notable divergence from a broadly constructive session in US equities. The S&P 500 proxy SPY closed at $764.29, up 0.85%; the Nasdaq 100 proxy QQQ closed at $714.88, up 0.87%; and the Dow 30 proxy DIA closed at $525.79, up 0.97%. In other words, this was a stock-specific move, not a market one.

One caveat on the quote itself: MEDGF's day range shows a single price of 150.06 at both the high and the low. That is characteristic of a thinly traded over-the-counter line rather than a deep, continuously quoted listing, and investors should be careful about reading too much precision into a one-print day. The percentage move is real; the liquidity behind it is not necessarily deep enough to call it a considered market verdict on the half.

Still, the direction is consistent with how equity markets typically treat this specific combination. A currency-flattered growth rate plus explicit margin pressure plus a soft largest market is a package that invites investors to discount the growth line and focus on the profit line — even when management expresses confidence about the recovery.

The checkpoints for the second half

Three things will settle whether this half was a wobble or the start of something:

• Does the US rebound arrive? Management said it is confident. The second-half US revenue line is the scoreboard. A recovery that shows up in procedure volume rather than in price would be the higher-quality version.
• Does the Spanish backlog convert? Deferred elective procedures should return. If they do not fully return, the strike was covering for weaker underlying demand in the market.
• Does the margin stabilise at constant currency? If the compression is currency plus growth investment, the constant-currency margin should hold or improve even while the reported margin does not. If the constant-currency margin also erodes, the problem is pricing or mix — and that is a far more durable headwind than an exchange rate.

For now, Medacta has delivered a growth rate most of its larger competitors would accept, and paid for it with a compressed margin and a shareholder base that wants to see the United States turn before it re-rates the story.

Key facts

• H1 2026 revenue growth: Nearly 10% in constant currency
• MEDGF last price: 150.06, down 6.21% (as of 20:00 GMT, 11 Sep 2026)
• Previous close: 160.00
• Headwinds cited on the call: FX translation, US market softness, Spanish strikes

Frequently asked questions

How fast did Medacta grow in the first half of fiscal 2026?

Medacta reported revenue growth of nearly 10% in constant currency for the first half of its 2026 financial year. Constant currency removes the effect of exchange-rate movements, so the reported growth figure — which includes currency translation — was lower. Management flagged foreign-exchange headwinds alongside the growth number on its earnings call.

Why did MEDGF shares fall on 11 September 2026?

MEDGF last traded at 150.06, down 6.21% from a previous close of 160.00, on the day the first-half results were discussed. The decline came despite a broadly positive session for US equity benchmarks, suggesting the reaction was specific to the company's combination of margin pressure, US market softness and currency-flattered growth.

What does 'constant currency' mean in an earnings report?

Constant currency restates foreign revenue using a prior period's exchange rates, isolating underlying commercial performance from currency swings. For a Swiss-based company selling in dollars, euros and yen, it can show meaningfully higher growth than the reported figure. Investors generally treat it as useful for judging demand but not as a substitute for reported, cash-relevant results.

How significant are the Spanish strikes for Medacta?

Medacta cited strike action in Spain as a drag on the half. Strikes at hospitals typically postpone elective orthopaedic procedures such as hip and knee replacements rather than cancel them, so the revenue effect is usually a timing shift into a later period. The key test is whether that deferred volume converts in the second half.

What did Medacta say about the US market?

The company flagged softness in the US market during the half while expressing confidence in a rebound. The United States is the largest orthopaedic implant market globally, so weakness there carries more weight than in smaller geographies. Whether the recovery arrives through procedure volume rather than pricing will determine the quality of any second-half improvement.

How did the broad market perform on the same day?

US benchmarks closed higher on 11 September 2026. The S&P 500 proxy SPY closed at $764.29, up 0.85%; the Nasdaq 100 proxy QQQ closed at $714.88, up 0.87%; and the Dow 30 proxy DIA closed at $525.79, up 0.97%. Medacta's decline therefore ran counter to the day's overall market direction.

Sources

• Medacta Group SA (MEDGF) (H1 2026) Earnings Call Highlights: Double-Digit Growth, Margin ... — GuruFocus

Photo: Anna Shvets · Pexels Licence — source